Product
Day 1 Higher Dose
1 clinical trial
1 indication
Indication
Lassa feverClinical trial
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults and Children Residing in West AfricaStatus: Recruiting, Estimated PCD: 2026-08-01